XM không cung cấp dịch vụ cho cư dân của Mỹ.
R
R

Roche


Tin tức

Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial

BUZZ-Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial Updates ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN
A
R

Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial

BUZZ-Compugen down as Roche's 'anti-TIGIT' lung cancer drug fails trial ** U.S.-listed shares of Israel-based therapy developer Compugen CGEN.TA fall ~3% to $1.62 premarket ** Switzerland-based Roche's ROG.S drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday ** CGEN has colo
A
R

European shares fall on French election uncertainty; log weekly gain

UPDATE 2-European shares fall on French election uncertainty; log weekly gain For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window STOXX 600 down 0.2%, eyes on French election UK midcaps close at one-month high Aixtron rallies on strong orders Updated at 1600 GMT By Shristi Achar A, Sruthi Shankar and Jesus Calero July 5 (Reuters) - European shares fell on Friday, weighed down by losses in banks and energy stocks as investors became more caut
A
R
A
E
F
U
G

Roche Says FDA Approves Genentech’S Vabysmo Prefilled Syringe (Pfs)

BRIEF-Roche Says FDA Approves Genentech’S Vabysmo Prefilled Syringe (Pfs) July 5 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES GENENTECH’S VABYSMO PREFILLED SYRINGE (PFS) FOR THREE LEADING CAUSES OF VISION LOSS DESIGNED TO SIMPLIFY ADMINISTRATION, VABYSMO PFS PROVIDES RETINA SPECIALISTS A READY-TO-USE OPTIO VABYSMO PFS IS FIRST AND ONLY SYR
R

Roche Holding seen down on plan to halt lung cancer drug trial

BUZZ-Roche Holding seen down on plan to halt lung cancer drug trial ** Shares of Swiss drugmaker Roche Holding ROG.S seen down 2.3% in Julius Baer pre-market trade following its plans to halt trial for lung cancer treatment after 'disappointing' results ** The company said its antibody drug tiragolumab (anti-TIGIT) in combination with its Tecentriq
R
J

Roche to halt trial in latest setback for lung cancer immunotherapy

UPDATE 2-Roche to halt trial in latest setback for lung cancer immunotherapy Rewrites throughout, adds shares in paragraph 4 By Rachel More and Ludwig Burger BERLIN, July 4 (Reuters) - Roche ROG.S will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck & Co MRK.N , casting further doubt on the drug candidate pioneered by the Swiss company.
R
J

Roche to halt trial for lung cancer treatment after 'disappointing' results

Roche to halt trial for lung cancer treatment after 'disappointing' results BERLIN, July 4 (Reuters) - Roche ROG.S intends to halt a trial for combined lung cancer treatment using a new immunotherapy called tiragolumab after results fell short of efficacy targets, the Swiss drugmaker said on Thursday. The trial, dubbed SKYSCRAPER-06, evaluates tiragolumab plus Roche's established drug Tecentriq and chemotherapy.
R

Roche Halts Trial Of Skyscraper-06 Study Due To Reduced Efficacy

BRIEF-Roche Halts Trial Of Skyscraper-06 Study Due To Reduced Efficacy July 4 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE PROVIDES UPDATE ON PHASE II/III SKYSCRAPER-06 STUDY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER SKYSCRAPER-06 EVALUATING TIRAGOLUMAB PLUS TECENTRIQ AND CHEMOTHERAPY DID NOT MEET PRIMARY ENDPOINTS OF PROGRESSION-FREE SUR
R

Swiss stocks - Factors to watch on July 4

Swiss stocks - Factors to watch on July 4 ZURICH/GDANSK, July 4 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: UBS AG UBSG.S U.S. bank State Street STT.N has won a mandate to act as custodian bank for a multibillion-dollar compensation fund of the Swiss federal government that was previously at UBS, authorities said on Wednesday.
A
R
U
S

Roche sues Stanford University, cancer-detection startup over trade secrets

UPDATE 1-Roche sues Stanford University, cancer-detection startup over trade secrets Updates July 2 story to add response from Foresight in paragraph 3 By Blake Brittain July 2 (Reuters) - Roche ROG.S has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products.
R

Swiss stocks - Factors to watch on July 3

Swiss stocks - Factors to watch on July 3 July 3 - Here are some of the main factors that may affect Swiss stocks on Wednesday: Roche ROG.S Roche has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products COMPANY STATEMENTS Dormakaba DOKA.S - says René Peter appointed CFO ad interim ANALYSTS' VIEWS VAT GROUP AG VACN.S - JEFFERIES RAIS
R

Roche sues Stanford University, cancer-detection startup over trade secrets

Roche sues Stanford University, cancer-detection startup over trade secrets By Blake Brittain July 2 (Reuters) - Roche ROG.S has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products. Roche said in the complaint filed on Monday that Stanford University professors Maximilian Diehn and Ash Alizadeh, whose technology Roche acquired in 20
R

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S

Swiss stocks - Factors to watch on July 2

Swiss stocks - Factors to watch on July 2 ZURICH/GDANSK, July 2 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Tuesday: GIVAUDAN SA GIVN.S The company completed the acquisition of B.Kolormakeup & Skincare. LOGITECH INTERNATIONAL SA LOGN.S A chairperson informed the management board of the 2025 transition plan . PSP SWISS PROPERTY AG PSPN.S The company acquired a commercial property in Geneva for 58 million Swiss francs.
G
L
R
P

Financials lift Japanese shares on rate-hike speculation

Financials lift Japanese shares on rate-hike speculation By Brigid Riley TOKYO, July 2 (Reuters) - Japan's Nikkei share average rose on Tuesday, buoyed by financial sector stocks climbing on speculation that the Bank of Japan (BOJ) might raise interest rates again in the near future amid a weakening yen. The Nikkei .N225 was up 0.38% at 39,780.58 by the midday break.
R
U
J

Roche's Vabysmo Receives Positive Opinion For Extension Of Marketing Authorisation

BRIEF-Roche's Vabysmo Receives Positive Opinion For Extension Of Marketing Authorisation June 28 (Reuters) - ROCHE HOLDING AG ROG.S : EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION FOR EXTENSION OF VABYSMO® (FARICIMAB) POSITIVE OPINION FOR EXTENSION OF VABYSMO® (FARICIMAB) MARKETIN
R

Roche: CHMP Recommends EU Approval Of Roche's PiaSky For People With PNH

BRIEF-Roche: CHMP Recommends EU Approval Of Roche's PiaSky For People With PNH June 28 (Reuters) - ROCHE HOLDING AG ROG.S : CHMP RECOMMENDS EU APPROVAL OF ROCHE’S PIASKY FOR PEOPLE WITH PNH, A RARE, LIFE-THREATENING BLOOD CONDITION Source text for Eikon: ID:nGNE3NdDFn Further company coverage: ROG.S (Gdansk Newsroom)
R

EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older

BRIEF-EMA Says CHMP Gave Positive Opinion For mResvia RSV mRNA Vaccine For Prevention In Adults 60 Years And Older June 28 (Reuters) - Moderna Inc MRNA.O : EMA SAYS CHMP GRANTING A MARKETING AUTHORISATION FOR BALVERSA EMA: MRESVIA RSV MRNA VACCINE RECEIVED A POSITIVE OPINION FROM THE CHMP FOR PREVENTION IN ADULTS 60 YEARS OF AGE AND OLDER EMA: CHMP
P
R

Roche receives two new WHO prequalification designations, including HPV self-collection

BRIEF-Roche receives two new WHO prequalification designations, including HPV self-collection June 27 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE EXPANDS ACCESS TO CERVICAL CANCER SCREENING TOOLS WITH TWO NEW WHO PREQUALIFICATION DESIGNATIONS, INCLUDING HPV SELF-COLLECTION WORLD HEALTH ORGANIZATION (WHO) HAS AWARDED COBAS® HPV TEST PREQUALIFICATION
R

Roche's Ocrevus Subcutaneous Administration Approved By EU Commission

BRIEF-Roche's Ocrevus Subcutaneous Administration Approved By EU Commission June 25 (Reuters) - Roche Holding AG ROG.S : ROCHE’S OCREVUS SUBCUTANEOUS ADMINISTRATION APPROVED BY EUROPEAN COMMISSION, AS FIRST AND ONLY TWICE-A-YEAR INJECTION FOR RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS WORKING CLOSELY WITH NATIONAL HEALTH SYSTEMS IN EURO
R



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.